Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446144 | 0.89 | PYCR1 (0.48) | PYCR1KDM4ETDP1HTR2A | |
| SCHEMBL14037603 | 0.85 | KDM4E (0.53) | HMGCRKDM4ETDP1GLASMN1; SMN2 | |
| SCHEMBL3484403 | 0.84 | PYCR1 (0.53) | PYCR1KDM4ETDP1GLASMN1; SMN2 | |
| SCHEMBL29937640 | 0.83 | PYCR1 (0.49) | PYCR1KDM4ETDP1HTR2A | |
| SCHEMBL27488871 | 0.83 | PYCR1 (0.49) | PYCR1KDM4ETDP1HTR2ATSHR | |
| SCHEMBL11246 | 0.83 | PYCR1 (0.49) | PYCR1KDM4ETDP1HTR2A | |
| SCHEMBL1569750 | 0.83 | TAAR1 (0.61) | HTR2A | |
| SCHEMBL8163718 | 0.80 | HTR2A (0.63) | PYCR1KDM4ETDP1HTR2A | |
| SCHEMBL1125103 | 0.80 | PYCR1 (0.53) | PYCR1KDM4ETDP1HTR2ATSHR | |
| SCHEMBL30423333 | 0.80 | PYCR1 (0.53) | PYCR1KDM4ETDP1HTR2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| CN-101522192-A | Substituted imidazolone derivatives, preparation and uses | GENFIT (FR) | 2009-09-02 | — | — | CN | disclosed |
| EP-2049107-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | Genfit (FR) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | IPO5, PPIP5K2, IPO4 | PYCR1 1738/4885HMGCR 1943/4885KDM4E 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.